Note: This document contains side effect information about palifermin. Some of the dosage forms listed on this page may not apply to the brand name Kepivance.
Common side effects of Kepivance include: arthralgia, dysesthesia, edema, hyperesthesia, hypoesthesia, increased serum amylase, paresthesia, pruritus, skin rash, tongue edema, dysgeusia, erythema of skin, mouth discoloration, and tongue discoloration. See below for a comprehensive list of adverse effects.
Applies to palifermin: intravenous powder for solution
Along with its needed effects, palifermin (the active ingredient contained in Kepivance) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking palifermin:
Some side effects of palifermin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
Applies to palifermin: intravenous powder for injection
The most commonly reported side effects included all grades of elevated serum amylase, rash, treatment-emergent infections, and fever.
Very common (10% or more): All grades of elevated serum amylase (up to 62%), grades 3 and 4 elevated serum amylase (up to 38%), all grades of elevated serum lipase (up to 28%), mouth/tongue thickness/discoloration (up to 17%), grades 3 and 4 elevated serum lipase (up to 11%)
Common (1% to 10%): Oral fungal infection, oral paresthesia
Frequency not reported: taste disorder, tongue disorder
Postmarketing reports: mouth edema, tongue bumps, tongue edema, tongue redness
Peak amylase and lipase increases occurred during cytotoxic therapy, and usually returned to baseline by the day of hematopoietic stem cell infusion.
Most taste and tongue disorders were reversible and mild to moderate in severity, usually occurred within the first 6 days of treatment, and typically lasted 5 days.
Very common (10% or more): Rash (up to 62%), pruritus (up to 35%), erythema (up to 32%)
Common (1% to 10%): grade 3 skin rashes
Postmarketing reports: face edema, hand-foot syndrome, palmar-plantar erythrodysesthesia syndrome, skin hyperpigmentation
Very common (10% or more): Treatment-emergent infections (up to 50%), sepsis/septic shock (up to 12%)
Common (1% to 10%): Herpes virus infection, immunogenicity/antibody positivity
Approximately 50% of patients reported treatment-emergent infections when this drug was given 3 days prior to and 3 days after treatment with melphalan; 47% of patients given this drug 3 days prior to treatment with melphalan reported infections, and 25% of patients given placebo with melphalan reported infection.
Very common (10% or more): Fever (up to 39%), pain (up to 16%)
Very common (10% or more): Taste altered (up to 16%), dysesthesia (up to 12%), hyperesthesia (up to 12%), hypoesthesia (up to 12%), paresthesia (up to 12%)
Very common (10% or more): Edema (up to 28%)
Postmarketing reports: Edema on the soles, palmar edema
Very common (10% or more): Arthralgia (up to 10%)
Postmarketing reports: Vaginal edema, vaginal erythema
Postmarketing reports: Cataracts
Postmarketing reports: Allergic reactions, anaphylactic reactions
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Kepivance